---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-022791"
form_type: "8-K"
ticker: "CLDI"
cik: "0001855485"
company_name: "Calidi Biotherapeutics, Inc."
filed_at: "2025-08-08T23:59:59+00:00"
generated_at: "2026-05-17T16:46:54.344651+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Calidi Q2 net loss narrows to $5.7M; FDA Fast Track for CLD-201; raises $4.6M

## Summary
- Net loss $5.7M ($1.99/share) vs $7.4M ($16.75/share) in Q2 2024; R&D $2.6M, G&A $3.1M.
- Cash $5.3M at June 30, 2025, down from $9.6M at Dec 31, 2024; restricted cash $0.1M.
- FDA Fast Track Designation granted for CLD-201 for soft tissue sarcoma; Phase 1 IND opened Q1 2025.
- Raised $4.6M gross proceeds via warrant inducement; total 2025 raises $15.7M.
- Preclinical data for CLD-401 (RedTail platform) presented at ASCO; IND expected by end 2026.

## SEC filing metadata
- accession: 0001641172-25-022791
- form_type: 8-K
- ticker: CLDI
- cik: 0001855485
- company_name: Calidi Biotherapeutics, Inc.
- filed_at: 2025-08-08T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1855485/000164117225022791/0001641172-25-022791-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1855485/000164117225022791/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-022791
- JSON: https://secwatch.observer/filing/0001641172-25-022791.json
- Plain text: https://secwatch.observer/filing/0001641172-25-022791.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.